Is SYK a good stock to buy? We came across a bullish thesis on Stryker Corporation on MaxDividends’s Substack by Serhio MaxDividends. In this article, we will summarize the bulls’ thesis on SYK. Stryker Corporation’s share was trading at $313.68 as of June 24th. SYK’s trailing and forward P/E were 36.31 and 20.92 respectively according to Yahoo Finance.
smart.art/Shutterstock.com
Stryker Corporation (SYK) is a leading medical technology company with a broad presence across orthopedics, neurotechnology, spine products, surgical equipment, and medical devices used daily in hospitals, ambulatory surgery centers, and specialty clinics worldwide. The company has built one of the strongest franchises in healthcare through a combination of innovation, acquisitions, and deep integration into clinical workflows, creating a durable competitive position supported by recurring demand and high customer retention.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Unlike businesses dependent on a single product cycle, Stryker benefits from a diversified portfolio that spans implant systems, surgical instruments, and capital equipment, allowing it to participate across multiple areas of patient care while benefiting from ongoing procedure growth and equipment replacement cycles. The company’s financial strength is reflected in its Financial Score of 98, while shareholders have benefited from 16 consecutive years of dividend increases.
Stryker currently pays an annual dividend of $3.52 per share, representing a 1.17% yield and a conservative 40.74% payout ratio, leaving substantial capacity for continued investment in research, development, acquisitions, and future dividend growth. In the first quarter of 2026, the company reported net sales of $6.0 billion, up 2.6% year over year, organic sales growth of 2.4%, adjusted EPS of $2.60, a 15.5% operating margin, and a 21.1% adjusted operating margin.
Although a late-quarter cyber incident temporarily disrupted revenue timing, underlying demand remained strong enough for management to maintain full-year guidance of 8.5% organic sales growth and adjusted EPS of $14.90 to $15.10. The bullish thesis rests on Stryker’s entrenched position in healthcare systems, strong brand loyalty among surgeons, recurring procedure-driven demand, expanding product portfolio, and consistent innovation.
As hospitals continue investing in efficiency, patient outcomes, and advanced medical technologies, Stryker appears well positioned to compound earnings, cash flow, and shareholder returns over the long term.
Previously, we covered a bullish thesis on Medtronic plc (MDT) by Investing Intel in May 2025, which highlighted robust FY2025 results and the planned diabetes spin-off to unlock value through a more focused portfolio. MDT stock price has depreciated by approximately 0.68% since our coverage. Serhio MaxDividends shares a similar view but emphasizes Stryker’s diversified procedural exposure, durable hospital demand, and compounding dividend-driven returns in a high-quality medtech franchise.
Stryker Corporation is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 81 hedge fund portfolios held SYK at the end of the first quarter which was 67 in the previous quarter. While we acknowledge the risk and potential of SYK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SYK and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
